1.	BKM120 as Second-line Therapy for Advanced Endometrial Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBKM120C2201, 2010-022015-19, NCT01289041
2.	Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients Phase: Phase I Type: Treatment Status: Completed Age: 14 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBKM120X2101, 2008-002652-17, NCT01068483
3.	PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: VICC BRE 1055, NCT01248494
4.	A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBKM120X1101, NCT01283503
5.	A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CBEZ235A2118, 2010-022331-11, NCT01285466